Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

What this study is testing ClinicalTrials.gov NCT06640972 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002. The main question it aims to answer is if treatment with RDX-002 will lower triglycerides after a high-fat meal in patients who have recently stopped treatment with semaglutide or tirzepatide for obesity. The trial will also examine the effect of RDX-002 on body weight and fasting levels of cholesterol. Researchers will compare RDX-002 to a placebo (a look-alike substance that contains no drug) to see if RDX-002 works to reduce triglycerides. Participants will: Take drug RDX-002 or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests

Treatments tested

• RDX-002 Drug

  Gut-specific microsomal triglyceride transfer protein (MTP) inhibitor

• Placebo Drug

  Matching placebo